A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy
| Autor: | Young Hun Jeong, Jinah Jang, Yona Kim, Sung Hye Park, Hyo Eun Moon, Yeong-Jin Choi, Hyewon Youn, Dong-Woo Cho, Hee-Gyeong Yi, Kyung Shin Kang, Mihyeon Bae, Sun Ha Paek |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Biomedical Engineering Medicine (miscellaneous) Bioengineering Extracellular matrix 03 medical and health sciences 0302 clinical medicine Tissue engineering Cell Line Tumor Lab-On-A-Chip Devices Temozolomide Tumor Microenvironment Medicine Humans Decellularization business.industry Brain Neoplasms Bioprinting Cancer Brain Endothelial Cells Drug Synergism Chemoradiotherapy medicine.disease Computer Science Applications Gene Expression Regulation Neoplastic Oxygen Drug Combinations 030104 developmental biology Cell culture Cancer research Drug Evaluation business Glioblastoma 030217 neurology & neurosurgery Ex vivo Biotechnology medicine.drug |
| Zdroj: | Nature biomedical engineering. 3(7) |
| ISSN: | 2157-846X |
| Popis: | Patient-specific ex vivo models of human tumours that recapitulate the pathological characteristics and complex ecology of native tumours could help determine the most appropriate cancer treatment for individual patients. Here, we show that bioprinted reconstituted glioblastoma tumours consisting of patient-derived tumour cells, vascular endothelial cells and decellularized extracellular matrix from brain tissue in a compartmentalized cancer–stroma concentric-ring structure that sustains a radial oxygen gradient, recapitulate the structural, biochemical and biophysical properties of the native tumours. We also show that the glioblastoma-on-a-chip reproduces clinically observed patient-specific resistances to treatment with concurrent chemoradiation and temozolomide, and that the model can be used to determine drug combinations associated with superior tumour killing. The patient-specific tumour-on-a-chip model might be useful for the identification of effective treatments for glioblastoma patients resistant to the standard first-line treatment. A tumour-on-a-chip model featuring patient-derived glioblastoma cells, vascular endothelial cells and decellularized extracellular matrix from brain tissue can be used to identify patient-specific resistance to standard chemoradiotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|